CYP2D6 and nemaline myopathy: Notably, the low level of endoxifen detected in large proportion of patients with predicted NM phenotypes in our study may suggest the need for therapeutic drug monitoring (TDM) of endoxifen in addition to genotyping for the common functional CYP2D6 variant alleles.